A recent study led by researchers at the University Hospitals Case Medical Center Seidman Cancer Center reported a new promising therapeutic strategy based on adoptive immunotherapy for advanced melanoma. The study was published in the Journal of Immunotherapy and is entitled “T Cells Derived From Human Melanoma Draining Lymph Nodes Mediate Melanoma-specific Antitumor Responses In Vitro and In Vivo in Human Melanoma Xenograft Model”.
MRV Research
Targeted Therapies, Combination Protocols Are Revolutionizing Treatment for Advanced Melanoma
The treatment landscape for advanced melanoma is expanding dramatically. Just a few years ago, we had little to offer patients. Nothing showed a survival benefit. But over the past few years, the FDA has approved a handful of new agents that improve treatment response and overall and progression-free survival. Although a number of patients have had amazing responses to immunotherapy, there still are a number of them who do not respond to these agents. In addition, targeted therapy can only be used in select patient populations, and responses are not as durable as desired. Thankfully, preclinical research into novel agents and clinical trials are flourishing.
Questioning the link between citrus fruit and skin cancer
A research article titled ‘Citrus Consumption and Risk of Cutaneous Malignant Melanoma’ was just published online in the Journal of Clinical Oncology (1). You may have seen the several news headlines associated with the research. It caught my eye, as this relationship was news to me. Given that the results of the research would add a caveat to current cancer prevention recommendations, which encourage 5 or more servings per day of fruits and vegetables, it is worthwhile to break the study down.
Trovagene launches study to monitor response to immunotherapy in patients with melanoma
Trovagene has launched a study to determine the utility of the company’s cancer monitoring technology in predicting response to treatment in patients with advanced melanoma who are receiving one or a combination of therapies of Yervoy and Opdivo, according to a press release.